Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: A phase I/II study

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 1, 2010, Pages 150-155

  Koukourakis, Michael I ^a   Giatromanolaki, Alexandra ^a   Pitiakoudis, Michael ^a   Kouklakis, George ^a   Tsoutsou, Pelagia ^a   Abatzoglou, Ioannis ^a   Panteliadou, Marianthi ^a   Sismanidou, Kyriaki ^a   Sivridis, Efthimios ^a   Boulikas, Teni ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Regulon   (Greece)

Author keywords

Chemotherapy; Gastric cancer; Lipoplatin; Liposomal cisplatin; Radiotherapy

Indexed keywords

5-FLUOROURACIL; CIS-PLATIN; COMPLETE RESPONSE; COMPUTED TOMOGRAPHY; FOUR CYCLES; GASTRIC CANCERS; LIPOPLATIN; NEPHROTOXICITY; NEUTROPENIA; PERFORMANCE STATUS; RADIO-SENSITIZATION; RESPONSE RATE;

COMPUTERIZED TOMOGRAPHY; PATIENT MONITORING; PLATINUM; PLATINUM COMPOUNDS; RADIOTHERAPY; SURVEYS; TUMORS;

CHEMOTHERAPY;

CISPLATIN; FLUOROURACIL; FOLINIC ACID; LIPOPLATIN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIVITY; STOMACH CANCER; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; KIDNEY; LEUCOVORIN; MALE; MIDDLE AGED; NEUTROPENIA; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; STOMACH NEOPLASMS;

EID: 77955927320     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1733     Document Type: Article

References (21)

1. S.A. Hundahl, J.L. Phillips, and H.R. Menck The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis Cancer 88 2000 921 932
2. C.C. Earle, and J.A. Maroun Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials Eur J Cancer 35 1999 1059 1064
3. K.G. Janunger, L. Hafström, and B. Glimelius Chemotherapy in gastric cancer: A review and updated meta-analysis Eur J Surg 168 2002 597 608
4. J.S. Macdonald, S.R. Smalley, and J. Benedetti Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725 730
5. Fuchs C, Tepper JE, Niedwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): Interim toxicity results from Intergroup trial CALGB 80101. American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, January 26-28, 2006, San Francisco, CA, A-61 (abstract).
6. A.J. Lacave, J. Wils, and E. Diaz-Rubio cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group Eur J Cancer Clin Oncol 21 1985 1321 1324
7. A. Gabizon, R. Catane, and B. Uziely Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 1994 987 992
8. S. Stewart, and K.J. Harrington The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors Oncology 11 Suppl 11 1997 33 36
9. M.I. Koukourakis, S. Koukouraki, and A. Giatromanolaki Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer J Clin Oncol 17 1999 3512 3521 (Pubitemid 29517922)
10. G.P. Stathopoulos, T. Boulikas, and M. Vougiouka Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study Oncol Rep 13 2005 589 595
11. T. Boulikas Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts Oncol Rep 12 2004 3 12
12. M.E. Froudarakis, A. Pataka, and P. Pappas Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma Cancer 113 2008 2752 2760
13. S.R. Smalley, L. Gunderson, and J. Tepper Gastric surgical adjuvant radiotherapy consensus report: Rationale and treatment implementation Int J Radiat Oncol Biol Phys 52 2002 283 293
14. P. Devarajan, R. Tarabishi, and J. Mishra Low renal toxicity of Lipoplatin compared to cisplatin in animals Anticancer Res 24 2004 2193 2200
15. A.K. Marr, I.D. Kurzman, and D.M. Vail Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs Am J Vet Res 65 2004 1 5
16. C. Arienti, A. Tesei, and A. Ravaioli Activity of lipoplatin in tumor and in normal cells in vitro Anticancer Drugs 19 2008 983 990
17. T. Boulikas, G.P. Stathopoulos, and N. Volakakis Systemic Lipoplatin infusion results in preferential tumor uptake in human studies Anticancer Res 25 2005 3031 3039
18. D.M. Brizel, and R. Esclamado Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: Consensus, controversy, and conundrum J Clin Oncol 24 2006 2612 2617
19. N.R. Datta, and S. Agrawal Does the evidence support the use of concurrent chemoradiotherapy as a standard in the management of locally advanced cancer of the cervix, especially in developing countries? Clin Oncol (R Coll Radiol) 18 2006 306 312
20. J. Tey, M.F. Back, and T.P. Shakespeare The role of palliative radiation therapy in symptomatic locally advanced gastric cancer Int J Radiat Oncol Biol Phys 67 2007 385 388
21. R. Suwinski, I. Wzietek, and R. Tarnawski Moderately low alpha/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy Int J Radiat Oncol Biol Phys 69 2007 793 799